Literature DB >> 24511108

Genetic alterations and personalized medicine in melanoma: progress and future prospects.

Klaus G Griewank1, Richard A Scolyer, John F Thompson, Keith T Flaherty, Dirk Schadendorf, Rajmohan Murali.   

Abstract

High-throughput sequencing technologies are providing new insights into the genetic alterations involved in melanomagenesis. It appears likely that most genetic events important in the pathogenesis of melanoma will be discovered over the next few years. Genetic analysis is also increasingly being used to direct patient care. In parallel with the discovery of new genes and the elucidation of molecular pathways important in the development of melanoma, therapies targeting these pathways are becoming available. In other words, the age of personalized medicine has arrived, characterized by molecular profiling of melanoma to identify the relevant genetic alterations and the abnormal signaling mechanisms involved, followed by selection of optimal, individualized therapies. In this review, we summarize the key genetic alterations in melanoma and the development of targeted agents against melanomas bearing specific mutations. These developments in melanoma serve as a model for the implementation of personalized medicine for patients with all cancers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24511108     DOI: 10.1093/jnci/djt435

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  22 in total

Review 1.  [Molecular and immunohistochemical diagnostics in melanoma].

Authors:  B Schilling; K G Griewank
Journal:  Hautarzt       Date:  2016-07       Impact factor: 0.751

Review 2.  Cell Cycle Regulation and Melanoma.

Authors:  Wen Xu; Grant McArthur
Journal:  Curr Oncol Rep       Date:  2016-06       Impact factor: 5.075

Review 3.  CDK4 inhibitors an emerging strategy for the treatment of melanoma.

Authors:  Belinda Lee; Grant A McArthur
Journal:  Melanoma Manag       Date:  2015-08-10

Review 4.  Predicting the outcome of melanoma: can we tell the future of a patient's melanoma?

Authors:  Oriol Yélamos; Pedram Gerami
Journal:  Melanoma Manag       Date:  2015-08-10

5.  mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model.

Authors:  Adi Sharbi-Yunger; Mareike Grees; Esther Tzehoval; Jochen Utikal; Viktor Umansky; Lea Eisenbach
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

6.  Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma.

Authors:  Yuuki Iida; Aaron Ciechanover; Diego M Marzese; Keisuke Hata; Matias Bustos; Shigeshi Ono; Jinhua Wang; Matthew P Salomon; Kevin Tran; Stella Lam; Sandy Hsu; Nellie Nelson; Yelena Kravtsova-Ivantsiv; Gordon B Mills; Michael A Davies; Dave S B Hoon
Journal:  Clin Cancer Res       Date:  2017-04-07       Impact factor: 12.531

7.  Novel insights into the pathogenesis and treatment of NRAS mutant melanoma.

Authors:  Jeffrey Zhao; Carlos Galvez; Kathryn Eby Beckermann; Douglas B Johnson; Jeffrey A Sosman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2021-08-11

Review 8.  [Molecular diagnostics of melanomas].

Authors:  K G Griewank
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

Review 9.  Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.

Authors:  Jennifer A Wargo; Alexandre Reuben; Zachary A Cooper; Kevin S Oh; Ryan J Sullivan
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

10.  Identification of translational dermatology research priorities in the U.K.: results of an electronic Delphi exercise.

Authors:  S J Brown; S M Langan; S G Nicholls; K Shams; E Healy; N J Reynolds
Journal:  Br J Dermatol       Date:  2015-10-14       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.